A fost efectuată o analiză a terapiei contemporane a migrenei, revizuirea datelor preclinice şi clinice în managementul migrenei, cu prezentarea rezultatelor studiului clinic în baza fişelor de observaţie a pacienţilor cu migrenă cronică. Tratamentul migrenei a evoluat în ultimul deceniu, au fost avansate substanţial multe abordări noi antimigrenoase, inclusiv introducerea agoniştilor selectivi ai receptorilor 5-hidroxitriptamină 1B/1D (5-HT1B/1D). Lansarea sumatriptanului a fost ulterior urmată de apariţia unei serii de noi compuşi agonişti serotoninergici, de generaţia doua (5-TH B/D): almotriptan, eletriptan, frovatriptan, naratriptan, zolmitriptan şi o nouă clasă de medicamente, de generaţia a treia, agoniştii receptorilor 5-HT (1F), cum ar fi LY344864.

Modern pharmaco- and phytotherapy of the migraine It was made an analysis of contemporary therapy of migraine, a review of preclinical and clinical data of a new migraine management, presenting clinical trial results based on the information from the observation files of patients with chronic migraine. Migraine treatment has evaluated in the last decade, several new approaches to the treatment of migraine have been substantially advanced, including selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonists, the launch of sumatriptan was later followed by the appearance of a series of new compounds serotonin agonists, second generation (5-TH B/D): almotriptan, eletriptan, frovatriptan, naratriptan, zolmitriptan and a new class of drugs 5-HT(1F) receptor agonists, called third generation, such as LY344864.